3.28
price up icon0.92%   0.03
after-market Dopo l'orario di chiusura: 3.30 0.02 +0.61%
loading
Precedente Chiudi:
$3.25
Aprire:
$3.3
Volume 24 ore:
23,120
Relative Volume:
0.49
Capitalizzazione di mercato:
$11.98M
Reddito:
-
Utile/perdita netta:
$-60.61M
Rapporto P/E:
-3.6444
EPS:
-0.9
Flusso di cassa netto:
$-22.91M
1 W Prestazione:
+1.86%
1M Prestazione:
+23.77%
6M Prestazione:
+624.06%
1 anno Prestazione:
+356.63%
Intervallo 1D:
Value
$3.13
$3.30
Intervallo di 1 settimana:
Value
$3.13
$3.49
Portata 52W:
Value
$0.0815
$4.44

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
Nome
Bioline Rx Ltd Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
28
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
BLRX's Discussions on Twitter

Confronta BLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BLRX
Bioline Rx Ltd Adr
3.28 11.98M 0 -60.61M -22.91M -0.90
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.03 129.44B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.52 61.42B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
615.11 38.44B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.81 33.29B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.75 26.95B 3.81B -644.79M -669.77M -6.24

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2017-05-18 Aggiornamento Maxim Group Hold → Buy
2017-02-13 Iniziato Rodman & Renshaw Buy
2016-08-12 Downgrade Maxim Group Buy → Hold
2015-08-17 Reiterato Maxim Group Buy
2015-07-27 Reiterato ROTH Capital Buy
2015-06-22 Iniziato JMP Securities Mkt Outperform
Mostra tutto

Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie

pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Secures $25M Upfront in Major Licensing Deals, Extends Cash Runway to 2026 - Stock Titan

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024
pulisher
Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024
pulisher
Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register

Nov 25, 2024
pulisher
Nov 25, 2024

Options Volatility and Implied Earnings Moves Today, November 25, 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 22, 2024

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow

Nov 21, 2024
pulisher
Nov 20, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga

Nov 20, 2024
pulisher
Nov 20, 2024

BioLineRx to Report Q3 2024 Financial Results on November 25 - StockTitan

Nov 20, 2024
pulisher
Nov 12, 2024

BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks

Nov 12, 2024
pulisher
Nov 05, 2024

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

Nov 05, 2024
pulisher
Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com

Oct 24, 2024
pulisher
Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024
pulisher
Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024
pulisher
Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024
pulisher
Aug 23, 2024

Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research

Aug 23, 2024
pulisher
Aug 19, 2024

BioLineRx Schedules Annual Shareholders Meeting - TipRanks

Aug 19, 2024
pulisher
Aug 16, 2024

Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com India

Aug 16, 2024

Bioline Rx Ltd Adr Azioni (BLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.42
price down icon 5.24%
$67.87
price down icon 6.49%
$32.11
price down icon 2.70%
$24.20
price down icon 13.63%
$94.74
price down icon 6.29%
biotechnology ONC
$241.75
price down icon 4.88%
Capitalizzazione:     |  Volume (24 ore):